Loading…
Loading…
ELTP does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ELTP and 80,000+ other tickers.
See exactly how ELTP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ELTP and 80,000+ other tickers.
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products…
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
ELTP delivers record fiscal 2026 results, with stronger profits, improved cash and pipeline progress supporting its expanding generics platform.
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026"). Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year.
Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026 Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.